A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07109726

Title field or adapter rule

{'original_value': 'A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:30.002040+00:00

Published At

2026-10-28T00:00:00+00:00

Record Updated At

2026-10-28

Source Retrieved At

2026-10-31T22:18:19.086215+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Breast Cancer", "Endometrial Cancer", "Ovarian Cancer", "Lung Squamous Cell Carcinoma", "Head and Neck Squamous Cell Carcinoma", "Esophageal Squamous Cell Carcinoma", "Solid Tumor", "Cervical Cancer"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-28", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT07109726"

protocolSection.identificationModule.officialTitle

"A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE1", "PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Breast Cancer (protocolSection.conditionsModule.conditions)
• Endometrial Cancer (protocolSection.conditionsModule.conditions)
• Ovarian Cancer (protocolSection.conditionsModule.conditions)
• Lung Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
• Head and Neck Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
• Esophageal Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
• Solid Tumor (protocolSection.conditionsModule.conditions)
• Cervical Cancer (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Combination Therapy Dose Escalation', 'Monotherapy Dose Escalation'], 'description': 'Oral Capsules', 'name': 'TER-2013', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Combination Therapy Dose Escalation', 'Combination Therapy Dose Expansion'], 'description': 'Fulvestrant 500 mg Intramuscular Injection', 'name': 'Fulvestrant injection', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Combination Therapy Dose Escalation', 'Combination Therapy Dose Expansion', 'Monotherapy Dose Escalation', 'Monotherapy Dose Expansion'], 'description': 'Oral tablets', 'name': 'TER-2013', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• TER-2013 (protocolSection.armsInterventionsModule.interventions[].name)
• Fulvestrant injection (protocolSection.armsInterventionsModule.interventions[].name)
• TER-2013 (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.